JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares S&P 500 Value ETF
IVE
|
+$2.05B |
| 2 |
iShares S&P 500 Growth ETF
IVW
|
+$1.92B |
| 3 |
iShares Core US Aggregate Bond ETF
AGG
|
+$1.13B |
| 4 |
iShares Russell 1000 Value ETF
IWD
|
+$1.1B |
| 5 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$1.06B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Japan ETF
BBJP
|
+$1.24B |
| 2 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$1.12B |
| 3 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$989M |
| 4 |
Microsoft
MSFT
|
+$973M |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$931M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.54% |
| 2 | Technology | 14.97% |
| 3 | Healthcare | 10.91% |
| 4 | Financials | 10.87% |
| 5 | Consumer Discretionary | 8.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
BERY
2626
DELISTED
Berry Global Group, Inc.
BERY
| $2.67M | ﹤0.01% |
86,336
-40,209
| -32% | -$1.47M |
2015 Q4
17 quarters
|
|
2627
Otter Tail
OTTR
$3.69B
| $2.67M | ﹤0.01% |
59,955
+25,233
| +73% | +$1.26M |
2016 Q4
13 quarters
|
|
2628
Voyager Therapeutics
VYGR
$151M
| $2.67M | ﹤0.01% |
291,377
+62,349
| +27% | +$716K |
2017 Q3
10 quarters
|
|
2629
Usana Health Sciences
USNA
$278M
| $2.67M | ﹤0.01% |
46,130
-50,511
| -52% | -$3.51M |
2013 Q2
27 quarters
|
|
2630
Simmons First National
SFNC
$3.28B
| $2.66M | ﹤0.01% |
144,765
-233,823
| -62% | -$5.31M |
2013 Q2
27 quarters
|
|
2631
PUT
Agios Pharmaceuticals
AGIO
$1.9B
| $2.66M | ﹤0.01% |
75,000
+50,000
| +200% | +$2.31M |
2019 Q3
2 quarters
|
|
|
RAVN
2632
DELISTED
Raven Industries Inc
RAVN
| $2.65M | ﹤0.01% |
124,981
+91,221
| +270% | +$2.67M |
2016 Q3
14 quarters
|
|
2633
Bread Financial
BFH
$3.76B
| $2.65M | ﹤0.01% |
98,543
+12,796
| +15% | +$871K |
2013 Q2
27 quarters
|
|
2634
First Trust Health Care AlphaDEX Fund
FXH
$1.13B
| $2.64M | ﹤0.01% |
35,677
+13,869
| +64% | +$1.13M |
2013 Q2
27 quarters
|
|
|
CMCT
2635
Creative Media & Community Trust
CMCT
$12.1M
| $2.64M | ﹤0.01% |
10
+1
| +11% | +$329K |
2017 Q3
10 quarters
|
|
|
CLVS
2636
PUT
DELISTED
Clovis Oncology, Inc.
CLVS
| $2.63M | ﹤0.01% |
414,000
+180,700
| +77% | +$1.45M |
2019 Q3
2 quarters
|
|
2637
Valmont Industries
VMI
$9.37B
| $2.63M | ﹤0.01% |
24,791
-7,938
| -24% | -$1.03M |
2013 Q2
27 quarters
|
|
2638
Signet Jewelers
SIG
$3.91B
| $2.63M | ﹤0.01% |
407,047
+296,286
| +268% | +$6.07M |
2013 Q2
27 quarters
|
|
2639
PUT
Ligand Pharmaceuticals
LGND
$5.89B
| $2.63M | ﹤0.01% |
57,868
-496,129
| -90% | -$28.1M |
2019 Q3
2 quarters
|
|
|
WPX
2640
DELISTED
WPX Energy, Inc.
WPX
| $2.63M | ﹤0.01% |
860,756
-391,523
| -31% | -$3.69M |
2013 Q2
27 quarters
|
|
2641
CALL
NIO
NIO
$8.69B
| $2.62M | ﹤0.01% |
941,500
-309,100
| -25% | -$1.15M |
2019 Q1
4 quarters
|
|
|
MRSN
2642
DELISTED
Mersana Therapeutics
MRSN
| $2.6M | ﹤0.01% |
17,867
-9,263
| -34% | -$1.62M |
2017 Q2
11 quarters
|
|
2643
Invesco S&P 500 Top 50 ETF
XLG
$12B
| $2.6M | ﹤0.01% |
133,190
+22,700
| +21% | +$511K |
2013 Q2
27 quarters
|
|
|
CSFL
2644
DELISTED
CenterState Bank Corporation Common Stock
CSFL
| $2.6M | ﹤0.01% |
150,722
+86,816
| +136% | +$1.88M |
2017 Q3
10 quarters
|
|
2645
Standard BioTools
LAB
$288M
| $2.59M | ﹤0.01% |
1,021,090
+992,781
| +3,507% | +$3.26M |
2016 Q4
13 quarters
|
|
2646
Sprouts Farmers Market
SFM
$5.99B
| $2.58M | ﹤0.01% |
139,034
-352,368
| -72% | -$5.91M |
2014 Q2
23 quarters
|
|
|
EB
2647
DELISTED
Eventbrite
EB
| $2.58M | ﹤0.01% |
353,324
+304,777
| +628% | +$5.14M |
2019 Q1
4 quarters
|
|
|
HAPN
2648
Happen Inc
HAPN
$1.79B
| $2.58M | ﹤0.01% |
328,498
+290,565
| +766% | +$3.24M |
2014 Q4
21 quarters
|
|
2649
Tennant Co
TNC
$1.17B
| $2.57M | ﹤0.01% |
44,414
+11,502
| +35% | +$848K |
2013 Q2
27 quarters
|
|
2650
Oxford Industries
OXM
$389M
| $2.57M | ﹤0.01% |
70,862
+36,124
| +104% | +$2.22M |
2015 Q4
17 quarters
|
|
Similar funds
JP Morgan Chase's Q1 2020 Portfolio in Review
As of Q1 2020, JP Morgan Chase held 6,012 positions worth $426B, down 21% from $536B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase deployed $14B of net new capital in Q1 2020, opening 362 new positions and adding to 2,382 existing holdings. Its largest new stake was NextEra Energy, Inc. 5.279% Corporate Units: 1,245,017 shares worth $54.9M.
By sector, the portfolio is most concentrated in Miscellaneous at 28% of assets, down from 28% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was JPMorgan BetaBuilders Japan ETF, an estimated $1.24B trimmed.
- JP Morgan Chase's largest Q1 2020 buy was NextEra Energy, Inc. 5.279% Corporate Units: 1,245,017 shares worth $54.9M.
- JP Morgan Chase added most to iShares S&P 500 Value ETF in Q1 2020, an estimated $2.05B increase.
- JP Morgan Chase's biggest Q1 2020 reduction was JPMorgan BetaBuilders Japan ETF, cutting an estimated $1.24B.
- JP Morgan Chase fully exited Liberty Property Trust in Q1 2020, selling an estimated $264M.
- JP Morgan Chase's ten largest holdings make up 18% of its $426B portfolio in Q1 2020.
- JP Morgan Chase opened 362 new positions and closed 692 in Q1 2020.
- JP Morgan Chase's portfolio value fell 21% quarter-over-quarter to $426B.
Based on JP Morgan Chase's 13F filing for Q1 2020, filed 12 May 2020.